Table 3.
Total seroprevalence distribution of female and male patients positive for HAV with respect to the total positive amount for each year is reported as a number and percentage (in brackets) during the pre-pandemic period (2015–2019).
| Years Gender |
2015 | 2016 | 2017 | 2018 | 2019 | 2015–2019 | Positive and Negative | Positive N. (%) |
|---|---|---|---|---|---|---|---|---|
| Female N. (%) | 833 (43.5) | 850 (38.6) | 865 (41.2) | 979 (43.5) | 991 (40.2) | 4518 (41.3) | n = 6218 | 4518 (72.7) |
| Male N. (%) | 1083 (56.5) | 1352 (61.4) | 1232 (58.5) | 1269 (56.5) | 1473 (59.8) | 6409 (58.7) | n = 8401 | 6409 (76.3) |
| Total positive N | 1916 | 2202 | 2097 | 2248 | 2464 | 10,927 | p -value | <0.001 |